Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 Form 10 - Q ( Mark One ) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31 , 2021 or □ TRANSITION REPORT UNDER SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Nevada to Commission file number : 001-37823 Kintara Therapeutics , Inc. ( Exact name of registrant as specified in its charter ) ( State or other jurisdiction of incorporation or organization ) 99-0360497 ( I.R.S. Employer Identification No. ) 12707 High Bluff Dr. , Suite 200 San Diego , CA ( Address of principal executive offices ) 92130 ( zip code ) ( 858 ) 350-4364 ( Registrant's telephone number , including area code ) N / A ( Former name , former address and former fiscal year , if changed since last report ) Title of Each Class Common Stock Securities registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ( s ) KTRA Name of Each Exchange on Which Registered The Nasdaq Capital Market Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No □ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( §232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes No □ Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or an emerging growth company . See the definitions of “ large accelerated filer , " " accelerated filer ” , “ smaller reporting company " , and " emerging growth company ” in Rule 12b - 2 of the Exchange Act . Large accelerated filer Non - accelerated filer Emerging growth company ☐ ✓ ☐ Accelerated filer Smaller reporting company If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) Yes No ☑ Number of shares of common stock outstanding as of May 11 , 2021 was 32,617,939 . ☐ ☐